There is some concern that administration of Neupogen will delay engraftment of non-myeloid cells after a stem cell transplant but a recent review found this not to be the case. It also found that G-CSF is beneficial in allogeneic as well as autologous transplantation. It did recommend that it be delayed for 5 days after transplantation because there was no difference in outcome between delaying it for up to 5 days or starting immediately after transplant. The administration of Neupogen in most studies was for variable periods, including for more than 14 days.
M Trivedi et al, Optimal use of G-CSF administration after hematopoietic SCT Bone Marrow Transplantation (2009) 43, 895–908
Smith TJ, Khatcheressian J, Lyman GH: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based, clinical practice guideline. J Clin Oncol 24:3187-3205, 2006
Lyman GH: Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: A review of the evidence. J Natl Compr Canc Netw 3:557-571, 2005